Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells


Targeted cancer therapy includes, amongst others, antibody-based delivery of toxic payloads to selectively eliminate tumor cells. This payload can be either a synthetic small molecule drug composing an antibody-drug conjugate (ADC) or a cytotoxic protein composing an immunotoxin (IT). Non-human cytotoxic proteins, while potent, have limited clinical… (More)
DOI: 10.3390/biomedicines6010028

3 Figures and Tables


  • Presentations referencing similar topics